Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Insider Sells $80,812.45 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Oxana Beskrovnaya sold 2,339 shares of the firm’s stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total value of $80,812.45. Following the completion of the transaction, the insider now owns 140,375 shares of the company’s stock, valued at approximately $4,849,956.25. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Dyne Therapeutics Stock Up 0.5 %

DYN opened at $36.59 on Friday. The business’s fifty day simple moving average is $41.07 and its 200 day simple moving average is $33.61. Dyne Therapeutics, Inc. has a 52 week low of $6.40 and a 52 week high of $47.45. The stock has a market cap of $3.20 billion, a PE ratio of -9.22 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.02. As a group, equities analysts anticipate that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Guggenheim raised their price objective on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. Oppenheimer reissued an “outperform” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. StockNews.com cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. JPMorgan Chase & Co. increased their price objective on Dyne Therapeutics from $39.00 to $43.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 9th. Finally, HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research report on Wednesday, September 4th. One equities research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $51.40.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Concurrent Investment Advisors LLC bought a new stake in shares of Dyne Therapeutics in the 1st quarter worth approximately $573,000. Sei Investments Co. bought a new stake in Dyne Therapeutics in the first quarter worth $693,000. Rafferty Asset Management LLC lifted its stake in Dyne Therapeutics by 17.7% in the fourth quarter. Rafferty Asset Management LLC now owns 164,041 shares of the company’s stock worth $2,182,000 after purchasing an additional 24,632 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new stake in Dyne Therapeutics during the first quarter valued at about $810,000. Finally, Commodore Capital LP bought a new position in shares of Dyne Therapeutics during the fourth quarter valued at about $11,970,000. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.